On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

We recently published a list of Jim Cramer Discusses These 11 Stocks & Reveals Why Tech Stocks Are Down. In this article, we ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Shares of Bristol Myers Squibb Co. BMY advanced 1.90% to $60.02 Friday, on what proved to be an all-around dismal trading ...

U.S. ethics disclosures made public on Friday from some of President Donald Trump’s top legal nominees, including the lawyer ...

Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...